Parseur Achieves SOC 2 Type II Compliance with Oneleet, Strengthening Enterprise-Grade Security for AI Document Processing

Parseur Achieves SOC 2 Type II Compliance with Oneleet, Strengthening Enterprise-Grade Security for AI Document Processing

AI document processing platform serving 10,000+ businesses globally meets security standards as enterprises demand greater accountability from AI vendors. SINGAPORE, Sept. 8, 2026 /PRNewswire/ -- Parseur, an AI-powered document processing platform,...

HBM9378/WIN378, an Ultra-Long-Acting Antibody Targeting TSLP, Achieves Positive Phase 2 Results in Asthma and Initiates Phase 3 Study

HBM9378/WIN378, an Ultra-Long-Acting Antibody Targeting TSLP, Achieves Positive Phase 2 Results in Asthma and Initiates Phase 3 Study

The POLARIS-1 study enrolled 147 patients with uncontrolled, moderate-to-severe asthma, and the interim analysis was conducted on the first 98 patients. The analysis demonstrated a half-life of up to 75 days, with clinical effects consistent with...

Complete Home Filtration Achieves Australia-First NSF/ANSI 42 Certification

Complete Home Filtration Achieves Australia-First NSF/ANSI 42 Certification

Australia's only whole-home filtration systems with complete-system certification across all three relevant areas of NSF/ANSI 42 SYDNEY, Sept. 8, 2026 /PRNewswire/ -- Australian whole-home water filtration company, Complete Home Filtration (CHF),...

Taiwan's HORIEN Accelerates Global Footprint: Achieves Three Thai FDA Class 4 Approvals and Secures U.S. Patent for Biodegradable Ureteral Stent

Taiwan's HORIEN Accelerates Global Footprint: Achieves Three Thai FDA Class 4 Approvals and Secures U.S. Patent for Biodegradable Ureteral Stent

Market-entry initiative targets qualified Thai distributors across dental, surgical, wound-care, and regenerative medicine channels, while solidifying global IP leadership in advanced urological biomaterials. TAICHUNG, Sept. 8, 2026 /PRNewswire/ --...

Cell Stem Cell: tBE-mediated Base Editing Therapy Achieves Durable Clinical Remission in Sickle Cell Disease and β-Thalassemia Across Different Genetic Backgrounds

Cell Stem Cell: tBE-mediated Base Editing Therapy Achieves Durable Clinical Remission in Sickle Cell Disease and β-Thalassemia Across Different Genetic Backgrounds

Following 100% transfusion independence in Chinese TDT patients, new study confirms tBE is equally safe and effective for African SCD patients and TDT patients from South/Southeast Asia. SHANGHAI, Sept. 8, 2026 /PRNewswire/ -- On September 7, 2026,...

PetroChina Achieves a Strong Start for "the 15th Five-Year Plan" Interim Operating Results for the First Half of 2026 Hit New Record Highs

PetroChina Achieves a Strong Start for "the 15th Five-Year Plan" Interim Operating Results for the First Half of 2026 Hit New Record Highs

HONG KONG, Aug. 30, 2026 /PRNewswire/ -- PetroChina Company Limited ["PetroChina" or the "Company", (HKSE: 00857; SSE: 601857)] announced that in the first half of 2026, the Company proactively responded to changes in the international situation and...

Neopharma Technologies Achieves ISO/IEC 42001:2023 AI Management System Certification for NEOVAULT® Global Diagnostics Platform

Neopharma Technologies Achieves ISO/IEC 42001:2023 AI Management System Certification for NEOVAULT® Global Diagnostics Platform

Certification strengthens the governance framework behind NEOVAULT® as Neopharma expands from Fit-for-Duty into broader human health diagnostics NEW YORK, Aug. 27, 2026 /PRNewswire/ -- Neopharma Technologies Ltd ("Neopharma") today announced that it...

Seaspan Achieves Investment Grade Rating Upgrade from KBRA

Seaspan Achieves Investment Grade Rating Upgrade from KBRA

SINGAPORE, Aug. 27, 2026 /PRNewswire/ -- Seaspan Corporation Pte. Ltd. (Seaspan), a global leader in marine transportation and the world's largest independent owner and operator of containerships, today announced that Kroll Bond Rating Agency (KBRA)...

Viva Biotech Announces Its 2026 Interim Results: AI Sparks New Paradigm in Drug R&D, CDMO Commercial Manufacturing Accelerates Revenue Growth

Viva Biotech Announces Its 2026 Interim Results: AI Sparks New Paradigm in Drug R&D, CDMO Commercial Manufacturing Accelerates Revenue Growth

Results Highlights for Interim Results ended 30 June 2026 Revenue reached RMB1,006.5 million, increasing by 21.0% YoY Gross profit amounted to RMB341.7 million, increasing by 0.7% YoY Gross profit margin was 34.0% HONG KONG, Aug. 26, 2026...

Antengene Announces 2026 Interim Results: Achieves First‑Ever Profitability and Accelerates Value Creation Through Innovative R&D

Antengene Announces 2026 Interim Results: Achieves First‑Ever Profitability and Accelerates Value Creation Through Innovative R&D

SHANGHAI and HONG KONG, Aug. 24, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class...

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • ...
  • 13
  • menu
    menu